Hernandez Roman Jose, Patel Samarth
Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA, USA.
Division of Gastroenterology and Hepatology, Hunter Holmes McGuire VA Medical Center, Richmond, VA, USA; Division of Gastroenterology and Hepatology, Virginia Commonwealth University, 1200 E Broad St, Richmond, VA 23298-0342, USA.
Gastroenterol Clin North Am. 2020 Mar;49(1):95-104. doi: 10.1016/j.gtc.2019.10.001. Epub 2019 Dec 24.
Nonalcoholic fatty liver disease has been recognized as a major health burden. The efficacy and safety profile of pharmacotherapy in the treatment of nonalcoholic fatty liver disease remains uncertain; therefore, lifestyle modification is the first line of treatment. Based on available data, patients should optimally achieve at least a 5% to 10% weight reduction for histologic improvement. There is no clear consensus on the optimal diet or exercise regimen. Sustainability of any intervention is key to success; however, compliance has been a major issue in clinical trials. This finding underscores the importance of multidisciplinary strategies to achieve targeted weigh loss.
非酒精性脂肪性肝病已被公认为一项重大的健康负担。药物治疗在非酒精性脂肪性肝病治疗中的疗效和安全性仍不确定;因此,生活方式改变是一线治疗方法。根据现有数据,患者应最佳地实现至少5%至10%的体重减轻以获得组织学改善。关于最佳饮食或运动方案尚无明确共识。任何干预措施的可持续性是成功的关键;然而,依从性一直是临床试验中的一个主要问题。这一发现强调了多学科策略对于实现目标体重减轻的重要性。